At a Glance
- Companies: Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novartis, Sanofi
- Location: United States (federal drug pricing initiative)
- Headline figures: MFN‑linked discounts for Medicaid and cash‑pay patients; three‑year tariff exemptions for participating firms
- Focus area: Lowering prescription drug prices through “most‑favoured‑nation” (MFN) pricing and TrumpRx digital channel
- Next steps: Launch of TrumpRx platform in 2026, further negotiations with remaining large manufacturers
What happened?
The White House announced that TrumpRx, the administration’s discount drug initiative, has signed pricing agreements with nine additional pharmaceutical manufacturers. The new participants—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi—commit to offer selected medicines at reduced prices that align with “most‑favoured‑nation” benchmarks used in other high‑income countries.
Why does it matter?
The agreements extend a broader push to narrow the gap between US drug prices and those paid in Europe and other wealthy markets, particularly for Medicaid enrollees and cash‑pay patients. By tying discounts to MFN levels and routing offers through TrumpRx, the programme aims to create visible headline prices that could pressure traditional rebate‑driven pricing and improve affordability for high‑cost therapies.
Who’s behind it?
TrumpRx is a federal direct‑to‑consumer channel promoted by President Donald Trump as part of a suite of drug pricing reforms. The nine newly signed companies join earlier participants such as Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk and EMD Serono, meaning 14 of the 17 largest targeted manufacturers now have MFN‑based agreements with the administration.
How was it achieved?
Under the deals, manufacturers agree to provide MFN‑level discounts for qualifying drugs sold to Medicaid beneficiaries and to offer “deep discount” cash prices via TrumpRx, in exchange for three‑year exemptions from proposed tariffs on pharmaceuticals and related inputs. Some companies will also donate active pharmaceutical ingredients into the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), a federal stockpile intended to reduce reliance on foreign manufacturing during crises.
What’s next?
The Trump administration plans to launch the TrumpRx website, which will direct patients to discounted prices rather than dispensing medicines itself, with implementation expected from next year. Officials indicate they are continuing talks with AbbVie, Johnson & Johnson and Regeneron, the remaining large manufacturers yet to sign, while payers and pharmacies assess how MFN‑linked discounts and a parallel direct‑to‑patient channel might affect existing contracts.
What are people saying?
President Trump characterised the nine‑company deal as a “tremendous victory” for patient affordability and predicted that US drug prices would become the lowest in the developed world. Policy analysts note, however, that key implementation details remain unclear, including how MFN prices will be calculated and how the new discounts will interact with current Medicaid and commercial reimbursement structures.